Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04464954 · ClinicalTrials.gov registry record · NA

BFA Treatment of Pain

A NA study, sponsored by Paul Crawford.

Completed
Registry status
NA
Development phase
30
Enrollment target

NCT04464954: Completed NA study, sponsored by Paul Crawford.

NCT04464954 is a NA study that has completed, run by Paul Crawford. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04464954, a NA study, has completed, sponsored by Paul Crawford.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

The aim of this pilot study is to conduct an unblinded pilot randomized clinical study on the effectiveness and tolerability of auricular semi-permanent (ASP) vs intradermal (long), and pyonex needles in Battlefield Acupuncture (BFA) for the treatment of pain.

Primary Outcome

Defense and Veterans Pain Rating Scale (DVPRS).DVPRS is an 11-point numerical rating scale with 0 indicating no pain and 10 indicating severe pain. It has been confirmed for reliability and validity in measuring both acute and chronic pain, and is currently the standard for pain measurement throughout DoD and VA health systems. The DVPRS demonstrates linear scale qualities allowing parametric methods to be used.

Interventions

  • DEVICE Auricular semi-permanent (ASP gold) needles
  • DEVICE Intradermal (long) needles using J-type No. 2 (.18)x 15mm
  • DEVICE Pyonex needles (Seirin Yellow 0.2 x 0.6mm)

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2020-11-01
Est. Completion 2021-04-20
Phase NA
Paul Crawford

6 total trials

What the finished NCT04464954 record still lists

NCT04464954 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 3 interventions - of which Auricular semi-permanent (ASP gold) needles is the first listed.

NCT04464954 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04464954 about?

NCT04464954 is a clinical study titled "BFA Treatment of Pain". The aim of this pilot study is to conduct an unblinded pilot randomized clinical study on the effectiveness and tolerability of auricular semi-permanent (ASP) vs intradermal (long), and pyonex needles in Battlefield Acupuncture (BFA) for the treatment of pain.

What is the current status of trial NCT04464954?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2020-11-01. Estimated completion is 2021-04-20.

What interventions are being tested in trial NCT04464954?

The interventions under investigation include: Auricular semi-permanent (ASP gold) needles (DEVICE), Intradermal (long) needles using J-type No. 2 (.18)x 15mm (DEVICE), Pyonex needles (Seirin Yellow 0.2 x 0.6mm) (DEVICE).

Who is sponsoring clinical trial NCT04464954?

This trial is sponsored by Paul Crawford, which has 6 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04464954's enrollment target sits among peer trials

30 1593rd of 2000 higher than 299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04464954, the US trial registry maintained by the National Library of Medicine. NCT04464954 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.